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Summary 
The invariant chain (Ii) is associated with major histocompatibility complex class II molecules 
during early stages of their intracellular transport. In an acidic endosomal/lysosomal compart- 
ment, it is proteolytically cleaved and removed from class II heterodimers. Participation of as- 
partic and cysteine proteases has been observed in in vitro degradation of Ii, but the specific en- 
zymes responsible for its in vivo processing are as yet undefined. We have previously isolated a 
noncovalent complex of the lysosomal cysteine protease cathepsin L with a peptide fragment 
derived from the p41  form of Ii from human  kidney.  Here we show that this  Ii fragment, 
which is identical to the alternatively spliced segment of p41, is a very potent competitive in- 
hibitor of cathepsin L  (equilibrium inhibition constant K~ =  1.7  ￿  10 -12 M).  It inhibits two 
other cysteine proteases, cathepsin H  and papain, but to much lesser extent. Cysteine proteases 
cathepsins B, C, and S, as well as representatives of serine, aspartic, and metalloproteases, are 
not inhibited at a11. These findings suggest a novel role for p41 in the regulation of  various pro- 
teolytic activities during antigen processing and presentation. The Ii inhibitory fragment shows 
no sequence homology with the known cysteine protease inhibitors, and may, therefore, rep- 
resent a new class. 
M  HC class II molecules are transmembrane glycopro- 
.teins,  composed  of polymorphic  ~x  and  [3  chains, 
whose crucial function is to present bound antigenic pep- 
tides to CD4 + T  lymphocytes (1).  Shortly after their syn- 
thesis in the endoplasmic reticulum (ER) 1,  class II dimers 
associate  with  a  nonpolymorphic type  II  transmembrane 
protein called the invariant chain (Ii) (2). The resulting class 
II-Ii complexes exit the ER,  and are transported through 
the Golgi apparatus to the endocytic pathway (3, 4). 
Ii contributes in a number of ways to the proper func- 
tioning of MHC class II molecules. These include promot- 
ing effective association and folding of newly synthesized oL 
and  [3  subunits  (5),  increasing  transit  of assembled  het- 
erodimers out of the ER (6),  blocking of peptide binding 
1Abbreviations used in this paper: AS, additional segment of p41; CPI, cys- 
teine protease inhibitor; DTE, dithioerithritol;  Elk, endoplasmic reticu- 
lure; li, invariant  chain; k, pseudo first order rate constant; k~, second  or- 
der rate constant for complex formation; kai~, dissociation rate constant; 
Ki, equilibrium inhibition constant; Kin, Michaelis constant; -MCA, 
4-methyl-7-coumarylamide; vs, steady-state velocity;  vz, initial velocity; 
Z-, benzyloxycarbonyl. 
This paper is dedicated  to Professor  Hans Fritz  on the occasion  of  his 60th 
birthday. 
to class II molecules in the early compartments of the bio- 
synthefc pathway (7),  and sorting class II molecules into 
appropriate endocytic organelles (8, 9). 
After arrival in endosomes, the COOH-terminal lume- 
nal  domain  of Ii  is  degraded  in  distinct  steps  from  the 
COOH terminus of the molecule, resulting in the sequen- 
tial formation of processing intermediates, each lacking in- 
creasingly larger portions from the  COOH-terminal  side 
(10,  11).  This results in removal of li from class II dimers 
(3,  12). The specific proteases responsible for its processing 
remain  unknown,  but  in  vitro  degradation  of class II-Ii 
complexes  with  cathepsin  B  removes  Ii  and  allows  the 
binding of antigenic peptides to free class II molecules (12, 
13). Treatment of APCs with aspartic and cysteine protease 
inhibitors prevents complete proteolysis and dissociation of 
Ii from class II molecules (3,  11,  14). In B cells, an aspartic 
protease initiates Ii processing, whereas a cysteine protease 
completes the final stages  of Ii degradation,  as established 
using leupeptin and the specific aspartic  protease inhibitors 
(14). 
After the  dissociation of Ii,  class II  molecules assemble 
with  peptides  derived mainly  from  extraceUular antigens 
that enter the endocytic pathway by binding to specific re- 
ceptors, or through pinocytosis (15). Antigens are degraded 
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sequent competition among the resulting peptides leads to 
class II selection ofpeptides with the highest affinities (16). 
Little is known about the specific proteases responsible for 
the generation ofimmunogenic peptides, but it is very likely 
that they are antigen and class II allele dependent  (15). 
Endosomes comprise structurally and functionally distinct 
compartments,  and the actual vesicles involved in Ii cleav- 
age  and antigen  degradation  are as yet undefined.  Recent 
studies  (17)  have indicated that both class II molecules and 
Ii are introduced into the endocytic pathway at the level of 
the  early endosomes.  Other reports  (18,  19)  have  charac- 
terized  endosome-rdated  organelles,  distinct  from  iyso- 
somes  and from both  early and late  endosomes,  to which 
class II molecules are transported on their way to the plasma 
membrane. They arrive with an associated Ii, and leave the 
compartment devoid of it, but loaded with peptides (19). 
Ii  exists  in  humans  in  two  alternatively  spliced  forms, 
p31  (comprises p31  and p33, generated by alternative initi- 
ation of translation)  and p41  (comprises p41  and p43),  the 
latter  containing an additional  64-amino acid sequence in 
the  lumenal  domain  (20).  The  additional  segment  (AS)  is 
cysteine rich (20), and shares significant homology with the 
type  1 repetitive  sequence  of thyroglobulin  (21).  The p31 
and p41  forms are naturally occurring and are expressed at 
relative  levels  dependent  on  cell  type,  the  proportion  of 
p41  in relation to p31  varying from 9% in B  lymphocytes 
to 43% in epidermal Langerhans cells (22). 
An interesting feature ofli is that its various functions are 
associated with different functional regions contained in the 
Ii polypeptide. The endosomal locahzation signal can be at- 
tributed  to  the  NH2-terminal  cytoplasmic and  transmem- 
brane  domain  (8,  9);  class  II  association  is  mediated  by 
amino acids encoded by exon 3  (23); antigen presentation 
can be enhanced by the p41  form ofli (24, 25); and T  cell 
interaction can be mediated by the chondroitin sulfate form 
ofli (26). 
We have previously shown that a noncovalent complex 
of cathepsin L and the fragment derived from the p41 form 
of Ii can be isolated from human kidney (27). We now re- 
port on the structural organization of the complex, and on 
the  inhibitory  effect  of the  Ii  fragment  on  cathepsin  L, 
which is the most potent lysosomal cysteine protease. 
Materials and Methods 
Enzymes and Inhibitors.  The complex of cathepsin  L with the 
Ii fragment was isolated from human kidney (27). The Ii fragment 
was separated from the complex using reversed-phase  HPLC (27), 
freeze-dried on a speed-vac concentrator, and redissolved  in dis- 
tilled water.  Free  cathepsin  L was isolated from the same source 
(28). Cathepsins  B, H,  and  S were purified from human spleen 
(29),  cathepsin  C  from  human  kidney  (30),  and  cathepsin  D 
from human liver (31). Papain (papaya) and trypsin  (porcine pan- 
creas) were purchased from Sigma Chemical Co. (St. Louis, MO), 
and aminopeptidase  M  (porcine kidney) from Boehringer Mann- 
helm  (Mannheim,  Germany).  t-3-carboxy-trans-2,3-epoxypro- 
pyl-leucylamido-(3-guanidino) butane (Ep-475),  a specific inhibi- 
tor ofcysteine proteases used for active-site titrations, was a generous 
gift  from Dr.  Nobuhiko Katunuma  (University of Tokushima, 
Tokushima, Japan). 
Antibodies.  Polyclonal antibodies  against the li fragment were 
raised in rabbit and purified  by affinity chromatography oi1 pro- 
tein A-Sepharose (Pharmacia,  Uppsala, Sweden). 
COOH-terminal Sequence  Analysis.  Ii fragment was reduced with 
2-mercaptoethanol, alkylated with iodoacetic acid, and exposed to 
[~-tryptic cleavage. The resulting peptides  were identified  by their 
amino  acid  composition  using  an  amino  acid  analyzer  (model 
421; Applied Biosystems,  Foster City, CA). The sequence of the 
COOH-terminal peptide was determined using a hquid phase se- 
quenator (model 475A; Applied Biosystems). 
HPLC.  The components of the complex were separated  by 
HPLC (Milton Roy Co., Riviera Beach, FL) on a ChromSpher 
C8  column  (Chrompack  Int.,  Middelburg,  The  Netherlands) 
equilibrated  with 0.1% TFA, and eluted with a linear  gradient of 
acetonitrile  (0-70%)  in the starting solution. 
Affinity  Chromatography on Con A-Sepharose.  The  Ii fragment 
(a  mixture  of forms)  was  applied  to  Con A-Sepharose  equili- 
brated with 0.1 M sodium acetate buffer, pH 6.0, containing 1 M 
NAG1, 1 mM MgCI2, 1 mM CaCl> and 1 mM MnCl  2. Unbound 
proteins were washed offwith the same buffer, and bound mole- 
cules were eluted with 0.2 M methyl-o~-D-glucopyranoside  in the 
buffer. Unbound and bound fractions were concentrated, dialyzed, 
and subjected to SDS-PAGE. 
SDS-PAGE.  Electrophoresis  was  performed  using a Phast- 
System (Pharmacia).  Samples and molecular weight markers rang- 
ing from 14,400  to 94,000 M, (Pharmacia)  were run in the pres- 
ence of 5% SDS on an 8-25%-gradient polyacrylarmde gel (0.45 X 
43 X 50 mm). For reduction, 10% 2-mercaptoethanol was added 
to  samples. After  electTophoresis, the gel was stained  with  Coo- 
massie blue. 
Native PAGE.  Electrophoretic separation  was carried out un- 
der native conditions in 8  ￿  8-cm slabs of 12% homogeneous 
polyacrylamide gel in a buffer,  pH 4.5, containing 0.08 M 13-ala- 
nine and 0.04 M  acetic  acid.  The complex formed in vitro was 
made by mixing 10 ~M ofcathepsin L and 20 IxM of the li frag- 
ment in 20 mM sodium acetate buffer, pH 5.5, in the presence of 
8 mM dithioeritbritol (DTE) 20 rain before electrophoresis. 
Immunoblotting.  Proteins  were separated by SDS-PAGE as de- 
scribed above, and transferred  to Imobilon polyvinylidene difluo- 
ride  transfer  membrane  (Millipore  Corp.,  Bedford,  MA)  using 
passive  diffusion.  After immersion  of the  membrane  in  (t.1 M 
DTE for 5 min, nonspecific binding was blocked by preincubat- 
ing the blot in PBS containing 4% BSA. After washing,  the blot 
was  first  incubated  with  primary  anti-Ii  fragment  antibody, 
washed  again,  and  incubated  with  peroxidase-conjugated  goat 
anti-rabbit  IgG  (Jackson  ImmurloResearch  Labs.,  Inc.,  West 
Grove, PA). The blot was immunostained with 3-armno-9-ethyl- 
carbazole  (Sigma  Chemical Co.)  and hydrogen peroxide  in  50 
mM sodium acetate buffer, pH 5.0. 
Enzyme Assays.  Cathepsin L, cathepsin H, and papain activities 
were measured as described  below. All the other enzymes were 
assayed following standard  procedures using the substrate  benz- 
yloxycarbonyl (Z)-Phe-Arg-4-methyl-7-coumarylamide (-MCA) 
for cathepsins B and S, Gly-Phe-4-methoxy-~-naphthylamide for 
cathepsin C, hemoglobin for cathepsin  D,  Noa-benzoyi-oL-argi- 
nine-p-nitroanilide  for trypsin,  and  t-Leu-~-naphthylamide  for 
aminopeptidase  M.  Inhibitory  effects  of the  li  fragment  were 
studied  by incubating it with an enzyme for 30 min at 25~  be- 
fore the addition of a substrate. 
Active-site Titrations.  20 Ixl of cathepsin  L (0.1 IxM final pro- 
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mM DTE in 0.34 M  sodium acetate buffer, pH 5.5,  containing 
0.1% Brij-35 (polyoxyethylene-lauryl ether)  and  1 mM EDTA, 
and then added to 20 txl of increasing concentrations of the cys- 
teine protease inhibitor (CPI), Ep-475. After a 30-min incubation 
at 25~  450 p-I of 200 p-M Z-Phe-Arg-p-nitroanilide  in the same 
buffer was added. Product formation was followed continuously 
at 410 nm for 1 rain with a Lambda 3 spectrofluorirneter (Perkin- 
Elmer, Beaconsfield, UK). The velocity was calculated using lin- 
ear regression analysis, and the active concentration of cathepsin L 
determined from the plot of velocity against molar ratio of initial 
inhibitor and enzyme concentrations ([Io]/[Eo]). All the other en- 
zymes were active-site titrated in the same way using the corre- 
sponding substrates and inhibitors. The  Ii fragment was titrated 
with active-site-titrated cathepsin L. 
Inhibition Kinetics of Cathepsin L.  All experiments were carried 
out at 24~  under pseudo first  order conditions, with inhibitor 
concentrations at least 10-fold higher than enzyme concentrations 
(32). The progress curves were monitored continuously at excita- 
tion and emission wavelengths of 370 and 460 nm, respectively, 
using a spectrofluorimeter (model LS-50B;  Perkin-Elmer). The 
buffer used was 0.34 M sodium acetate buffer, pH 5.5, containing 
1 mM EDTA and 0.1% Brij-35. The reaction was started by the 
addition of 50 t~1 of the enzyme (6.6 pM final concentration, pre- 
activated with 8 mM DTE) to 2.450 ml of the buffer containing 
the substrate (Z-Phe-Arg-MCA) and the  inhibitor (the  Ii frag- 
ment).  Six different inhibitor concentrations and four different 
substrate concentrations were used. All progress curves were fit- 
ted by nonlinear regression analysis to the integrated rate equation 
(33):  P  =  vst  +  (vz  -  v~)(1  -  e-kt)/k,  where  P  represents the 
product concentration, vz and v~ are the initial and steady-state ve- 
locities, respectively, k is the observed pseudo first order rate con- 
stant, and t is time. The second order rate constant for complex 
formation, kas  ~, was calculated from the slope of the plot k versus 
[Io] (slope =  k~J(1  +  [So]/K~)), where Km is the Michaelis con- 
stant, using [So] =  Km =  2  p-M. The dissociation rate constant, 
kai~, was  obtained from individual measurements kai~s =  k%/v~, 
and the equilibrium inhibition constant, or K  i value, was calcu- 
lated from/~ =  kaiJk~,. 
Inhibition  Kinetics of Cathepsin H  and Papain.  Activities of ca- 
thepsin H  and papain in  the presence of the  Ii fragment were 
measured  under  the  same experimental conditions as described 
above for  cathepsin L,  using 0.1  M  phosphate buffer,  pH  6.8, 
containing  I  mM  EDTA,  and  the  substrate  H-Arg-MCA  (20 
IxM, 40 p-M) for cathepsin H  (23 pM final concentration, preac- 
tivated with 8 mM DTE), and 0.34 M sodium acetate buffer, pH 
5.5,  containing 1 mM EDTA, 0.1% Brij-35, and the substrate 
Z-Phe-Arg-MCA (10  p,M,  16  IxM, 20  p-M) for papain (30 pM 
final concentration, preactivated with 8 mM DTE). The inhibitor 
concentrations were  10-100-fold higher than the  enzyme con- 
centrations. Since v  z could not be determined due to very fast re- 
actions, only v~ was recorded and Ki values were determined from 
Dixon plots in the form 1/% versus [Io] at different substrate con- 
centrations (34). 
Results 
The li Fragment-Cathepsin  L  Complex.  The  NH 2-  and 
COOH-terminal sequences of the peptide fragment, sepa- 
rated from the complex, as well as its total amino acid com- 
position,  were  determined,  showing  it  to  originate  from 
the p41  form ofli (27, and Fig. 1). It is identical to AS en- 
coded by an alternatively spliced exon (20), which is found 
only in p41, and not in the major form ofli, p31  (Fig. 1). 
The fragment consists of 65 amino acid residues, starting at 
residue  194  and  ending  at  residue  258  (p41  numbering). 
The Ii fragment was eluted from the complex as a mixture 
of either two or three forms  (number and proportions de- 
pended  on  details in  purification procedure)  that  differed 
slightly in their molecular masses as revealed by immuno- 
blotting (Fig. 2 B). Amino acid compositions and the NH 2- 
terminal sequences of the two main bands were  shown  to 
be  identical.  Only  the  higher  molecular  mass  band  was 
bound to Con A-Sepharose, and was therefore concluded 
to be glycosylated. 
The  complex was  analyzed by SDS-PAGE  and  stained 
either with Coomassie blue (Fig. 2 A) or with anti-Ii frag- 
ment Ab (Fig. 2  B). In the presence of SDS (Fig. 2, A  and 
B, lane  1) the Ii fragment remained associated with the en- 
zyme, as revealed by anti-Ii immunostaining (Fig. 2  B, lane 
1).  The  complex  migrated  as  a  series  of bands,  a  conse- 
quence of the different forms of Ii fragment, with apparent 
molecular mass of ~32  kD.  After incubating with  SDS at 
100~  the complex dissociated, giving rise to new protein 
194 
N terminus:  LTKCQEEVSHIPAVHPGSFRPKCDEN  .  .  . 
258 
C terminus:  ￿9  ￿9  ￿9 GHHNCSES 
i 
1331  N%! 
I 
1341  NH, ! 
Inhibitory fragment 
216 
198  256 
!  ! 
ICOOH 
Figure  1.  NH 2-  (27)  and 
COOH-terminal amino acid se- 
quences  of  the  fragment  that 
binds to cathepsin L, a schematic 
representation  of p31  and  p41 
(20), and the position of the in- 
hibitory  fragment  within  p41 
(horizontal bar). (AS)  Additional 
segment  derived  from  alterna- 
tive  splicing, unique  to  p41. 
Numbering is according to p41. 
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ment-cathepsin L complex. (/t) 8-25% SDS-PAGE 
of the  complex stained with  Coomassie blue. (13) 
Immunoblot of the equivalent gel stained with the 
anti-li fragment antibody. Samples: (lane 1) nonre- 
duced complex; (lane 2) nonreduced complex ex- 
posed to 100~  in the presence of SDS for 5 min; 
and (lane 3) reduced complex exposed to 100~  in 
the presence of SDS for 5 min. 
bands  (Fig. 2, A  and B, lane 2), the one with apparent mo- 
lecular mass of 3l  kD being cathepsin L, and the two with 
apparent  molecular  masses  of ~14  kD  being  liberated  Ii 
fragments.  The  surprisingly  small  difference  in  apparent 
molecular masses of free and complexed cathepsin L reflects 
the stability of the complex towards SDS.  Immunostaining, 
which  is  more  sensitive  than  Coomassie  staining,  also 
showed the third  form of the Ii fragment.  After incubating 
the complex with SDS at 100~  under reducing conditions 
(Fig. 2, A  and B, lane 3), cathepsin L migrated as two bands 
with molecular masses of 25 kD (heavy chain)  and <14 kD 
(light  chain),  but  the  position  of the  Ii  fragment  did  not 
change.  In  lane  2,  traces  of reduced  cathepsin  L  can  be 
seen. 
Inhibitory Activity  of the B Fragment.  During  the  purifi- 
cation procedure it was observed that complexed cathepsin 
L  appeared much less active than  its flee counterpart  (27). 
To investigate its inhibitory  role,  free Ii fragment was ob- 
tained by separating the complex components using HPLC 
(27),  and  a  wide  range  of human  lysosomal  cysteine  pro- 
teases, cathepsins B, C, H, L, and S, the plant cysteine pro- 
tease,  papain,  as  well  as  representatives  of the  other  three 
classes of proteases,  cathepsin  D  (aspartic protease),  trypsin 
(serine protease),  and  aminopeptidase M  (metalloprotease), 
were  screened  for inhibition  (Fig.  3  A).  None  of the  en- 
zymes tested,  except cathepsin  L,  cathepsin  H, and papain, 
was inhibited,  even at inhibitor concentrations  of 10 -7 M. 
Inhibition Kinetics of Cathepsin L.  Since  cathepsin  L,  af- 
ter  dissociation  of the  Ii  fragment  from  the  complex  by 
HPLC,  was irreversibly denatured,  it was isolated in a  free 
form from the  same source,  human  kidney  (28).  Complex 
formation  in  vitro  with  the  Ii fragment was  confirmed  by 
native PAGE  (Fig. 4). The inhibition kinetics of the Ii frag- 
ment  with  cathepsin  L  were  characterized  under  pseudo 
first order conditions.  All progress curves showed an expo- 
nential  approach to a final,  steady-state rate, and were ana- 
lyzed  by  the  least-squares  fitting  of the  appropriate  inte- 
grated  rate  equation  (33)  to  the  experimental  data  (Fig.  3 
B). In a control experiment with the inhibitor omitted, flu- 
orescence increased linearly, verifying that the enzyme was 
stable during the experiment.  Dependence  of the observed 
k,  on  substrate  concentration  demonstrated  a  competitive 
inhibition  mechanism  (Fig.  3  C), and its linear dependence 
on inhibitor  concentration  allowed us to calculate  ka~  ~ (Fig. 
3  D).  k~s~, was  measured  directly,  and  Ki  was  calculated 
from/~  =  kaiss/h~,s~. It is evident  that the  Ii fragment binds 
very tightly (Ki =  1.7  X  10 -12 M) and rapidly (kas~ =  4.6  ￿ 
10  v M-is -I)  to  the  active  site  of cathepsin  L  (competitive 
inhibition,  Fig.  3  C)  in  contrast  to  the  weakly  inhibitory 
activity of intact p31  reported  elsewhere  (35).  To  confirm 
the accuracy of the value of/~, the slope of the plot (vJv~  - 
1)  versus  [Io] led  to  Ki  =  1.1  ￿  10 -12 M,  in  good  agree- 
ment with the value calculated from k~s  , and kales. 
The low activity of the complex as isolated is accounted 
for by the  concentration  of free enzyme expected  to  exist 
at  equilibrium  using  the  value  of K]  determined  from  the 
above  experiments.  This  confirms  the  close  similarity and 
probable identity between the complex as isolated,  and that 
generated in vitro. 
Inhibition Kinetics  of Cathepsin H  and Papain.  Under  the 
experimental conditions used, cathepsin H  and papain inhi- 
bition reactions were too fast to monitor the initial rates (Vz). 
Therefore,  only v, were recorded  (data not shown),  and the 
values were calculated by the equilibrium Dixon method 
(34). Binding of the Ii fragment to cathepsin H  (/~  =  5.3  ￿ 
10 -9 M) and to papain (/<] =  1.4  ￿  10 -9 M) was shown to 
be much weaker than binding to cathepsin L  (Fig.  3 A). 
Discussion 
We have isolated from human  kidney  and  characterized 
a  noncovalent  complex  between  the  lysosomal  cysteine 
protease,  cathepsin  L  and  a  peptide  derived  from  the  p41 
form of Ii. Although the complex was purified from a tissue 
homogenate,  there  are  good  reasons  to  believe  that  the 
complex must be formed in  vivo in  the  endocytic  vesicles 
of Ii-positive cells.  First,  Ii and  cathepsin  L  are colocalized 
in  the  cell:  class  II-li  complexes  are  transported  from  the 
ER  to endocytic  compartments  (10,  36-38),  and  the lyso- 
somal hydrolases  are present  all along this  endocytic  path- 
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Figure 3.  Inhibition kinetics of the p41 fragment. (A) Inhibition  of various proteases by the p41 fragment. The activities ofcathepsin L ([Eo] =  7 pM, 
filled drdes), papain ([Eo] =  30 pM, triangles),  cathepsin H ([Eo] =  23 pM, squares) and cathepsin B ([Eo] =  100 pM, open drdes) were measured in the pres- 
ence of varying amounts of the fragment. The activities of cathepsins C, S, and D, trypsin, and aminopeptidase M were also measured ([Eo] =  100 pM) 
and were the same as that ofcathepsin B. (B) Progress curves for the inhibition  ofcathepsin L ([Eo]= 6.6 pM, [So] =  2 IxM) with different inhibitor con- 
centrations: (1) [Io] =  0.066 nM, (it) [loJ =  0.132 nM, and (iit)  [Io] =  0.264 nM. (+) Experimental points; (solid  lines)  theoretical curvefits. (C) Depen- 
dence ofk for the interaction between cathepsin L and the Ii fragment, on substrate concentration ([/3o] =  0.064 nM, [Io] =  0.64 nM), and (D), on in- 
hibitor concentration ([Eo] =  6.6 pM, [So] =  2 IxM). The linearity of the plot in C indicates the competitive nature of the inhibition. 
way  (39).  Second,  the  value  of/~  is  sufficiently low  (K~ 
,"~10 -12 M)  to  ensure the formation of the complex at the 
likely physiological concentrations of enzyme and peptide. 
The K] value obtained for this interaction is comparable 
to the values reported for the inhibition ofcathepsin L with 
the endogenous CPIs from the cystatin superfamily, which 
are potent cytosolic regulators  of cysteine protease  activity 
(40).  The  inhibition of cathepsin  H  by the  li fragment  is 
significantly weaker  (Ki r  -9 M), indicating that it is less 
likely to be physiologically relevant. Since cathepsin L is by 
far the most potent cysteine protease ofendocytic compart- 
ments, its inhibition must be very important in the regula- 
tion of its various functions during antigen processing and 
presentation￿9 The  Ii fragment  shows  no  sequence homol- 
ogy to  any of the known  CPI  (40),  suggesting that it may 
represent a new class ofinhibitors. 
It is very interesting that  the inhibition is a  property  of 
AS, the unique sequence that occurs in p41, but not in p31 
(Fig.  1).  Few studies  have been made  on p41  (24,  25,  37, 
38),  and its biological significance, as well as that of AS,  is 
still unclear.  It has been shown  that  p41  is able  to  impart 
the  same  folding  and  peptide-blocking functions  as  does 
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p31  (25),  but is  superior in its  ability to  enhance  antigen 
presentation for a  subset of antigens (24).  It has been sug- 
gested  that  p41  might  contain  a  transport  signal  that,  in 
contrast to p31,  directs class II not only to early but to late 
Figure  4.  Formation  of  the  Ii 
fragment-cathepsin  L  complex  in 
vitro. Electrophoresis of proteins on 
a 12% polyacrylamide gel at pH 4.5 
under  native  conditions.  Samples: 
(lane  1)  the  complex  as  isolated; 
(lane 2) cathepsin L and the Ii frag- 
ment mixed together in the presence 
of 8 mM DTE 20 rain before elec- 
trophoresis; (lane 3) the Ii fragment; 
and (lane 4) cathepsin L. The com- 
plex formed in vitro and excess Ii are 
seen as separate bands in lane 2. endosomal  compartments  (24).  p41  would,  therefore,  en- 
hance  the  presentation  of immunogenic  peptides  that  are 
generated only after extensive proteolysis of the native anti- 
gen.  This  would  be  possible  only  in  highly  acidified  late 
endosomal  vesicles,  rich  in  proteases.  The  putative  trans- 
port signal would presumably be encoded in AS. From an- 
other observation that the half-life of p41  in the endosomal 
compartments is longer than  that  of p31,  it has been pro- 
posed that p41  might be more resistant to proteolysis rela- 
tive to p31  (38). This would enable p41  to penetrate more 
deeply into  the  endosomal system, and to survive in these 
more  proteolytically  active  compartments.  In  addition,  it 
has been  reported  that in vitro  digestion  of ovalbumin by 
cathepsins  B  and  L  destroyed  its  immunogenic  epitope, 
which is recognized in vivo by specific CD4 + T  cells (41). 
It has been proposed that in APCs, mechanisms must exist 
for the  protection  of epitopes from destructive  proteolysis 
in processing compartments. 
Our  finding,  that  AS  exhibits  strong  inhibitory  activity 
against cathepsin  L, illuminates  these  observations from an 
unexpected point of view. Since the class II-binding region 
of Ii presumably  involves  only  sequences  shared  by both 
p31  and p41  forms of Ii, it is highly likely that the AS re- 
gion  is  not  involved  in  this  interaction.  This  leads  to  the 
possibility that the inhibitory site for cathepsin L is available 
while p41  is still associated with the  class II molecule.  AS, 
the  additional  segment of 64  amino  acids,  unique  to p41, 
would  therefore  encode  the  domain  capable  of protecting 
class II-Ii complexes and antigenic epitopes from undesired 
proteolytic  action  of one  of the  most powerful  lysosomal 
proteases, cathepsin L, enabling them to survive in a harm- 
ful digestive milieu. 
It it interesting that AS shares significant homology with 
10  repetitive  type  1  sequences  of thyroglobulin,  which  is 
also targeted to lysosomes where,  under conditions  of lim- 
ited  proteolysis,  it  is  processed  to  two  thyroid  hormones 
(21).  For  some  other  proteins,  such  as  nidogen  (42)  and 
saxiphilin  (43),  insertions  of homologous  domains  have 
been  reported,  showing  that versions  of this  cysteine-rich 
structural  motif occur in  a variety of proteins,  differing in 
function. 
The  hypothesis  of simultaneous  association  of class  II, 
p41,  and  cathepsin  L  is  the  most  persuasive,  but  not  the 
only possible explanation  of our finding.  It is possible that 
p41  is first proteolytically degraded, yielding a product that 
binds  to  cathepsin  L  and  inhibits  its  activity.  In this  case, 
p41 would still regulate endosomal proteolytic activity dur- 
ing antigen processing and presentation.  The level of regu- 
lator would depend  on the relative proportions  of the two 
splicing  pathways  that  result  in  the  two  forms  of Ii.  It is 
worth  noting  that  all studies  on  Ii degradation  have been 
carried  out  either  on p31  or  on  the  mixture  p31/p41  (3, 
10-14).  No  data  are  available  solely  for  p41  processing, 
which would be helpful in evaluating both aforementioned 
hypothesis. 
It is also interesting that cathepsin B, which is thought to 
play a major role in antigen  and Ii processing  (11-14,  44), 
is not inhibited by the isolated Ii fragment.  It has been re- 
ported  that  in  rat  macrophages  under  certain  conditions, 
cathepsins B  and L  were found in different  endosomal/ly- 
sosomal subpopulations  (45),  which  would  allow  different 
roles for these two proteases. But even if they are not sepa- 
rately located, the specificity of inhibition shown in this pa- 
per would still strongly suggest that these two enzymes play 
different roles in class II-restricted antigen presentation. 
The  study  presented  here  indicates  that  the  biological 
role of Ii is not limited to the intensively studied functions 
connected  with  its  association  with  MHC  class  II dimers. 
The  novel  and  unexpected  fact  that  the  p41  form  of Ii 
yields a peptide  that is a very potent inhibitor  of cathepsin 
L  is worthy  of further  investigation.  The  future  task is  to 
define  the  precise site  and  mechanism  of complex forma- 
tion, as well as its genuine function within the cell. 
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